View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
May 24, 2018

China’s enrolment rate dips as phase rises

On average, enrolment rates for clinical trials in China, which include both single-country and multinational trials, decrease as products move through the pipeline.

By GlobalData Healthcare

Figure 1: Enrolment rate by trial phase in China. Credit: GlobalData.

On average, enrolment rates for clinical trials in China, which include both single-country and multinational trials, decrease as products move through the pipeline (Figure 1).

GlobalData looked at trials between January 2001 to April 2018 and found that Phase I trials have the highest enrolment rates, enrolling 15.5 subjects/site/month, and have the second largest number of trials, as shown by the bubble size in the figure below.

Phase III trials make up 54.8% of the total trials that were analysed, and have a low enrolment rate of 4.4 subjects/site/month. These later-stage trials often have such slow enrolment rates because they require the largest number of patients per trial.

For more insight and data, visit the GlobalData Report Store – Pharmaceutical Technology is part of GlobalData Plc.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU